Rhea-AI Summary
PharmaMar (MSE: PHM) announced the publication of a study in the Life Science Alliance journal on plitidepsin's efficacy against COVID-19. The research indicates that plitidepsin exhibits potent antiviral activity against SARS-CoV-2 variants, including Omicron, at low concentrations. In vivo studies showed a 99% reduction in viral loads in treated animals. The Phase I-II APLICOV-PC trial, involving 45 patients, confirmed safety and clinical efficacy, with 74% of moderate disease patients discharged within a week. These findings support the ongoing Phase III NEPTUNO trial in 17 hospitals across Europe and Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.69%
Tags
FAQ
What is the current stock price of PHARMA MAR SA NEW (PHMMF)?
PHARMA MAR SA NEW (PHMMF) last closed at $94.6.
What is the market cap of PHARMA MAR SA NEW (PHMMF)?
The market cap of PHARMA MAR SA NEW (PHMMF) is approximately $1.7B.